Warner-lambert Company

Merck + Co., Inc.

Russell U Nesbitt

Mahdi B Fawzi

Isaac Ghebre-Sellassie

Suk-Zu Song

Michael Ray Harris

Surendra C Mehta

Jay Weiss

Kuchi S Murthy

Nouman A Muhammad

Zahra A Rashidbaigi

Nancy L Mills

Robert H Gordon

John E Botzolakis

Steven B Silbering

Majid Mahjour

James B Williams

Uma R Iyer

Sadath U Khan

Robert G Reisch, Jr

Phyllis Ying

Marilyn A Apfel

Bernadette Tedeschi

Mary E Trapold

Rowland P Blythe, Jr

Maryann Mench

Riten Parikh

A novel solid pharmaceutical dispersion that improves the bioavailability of poorly water soluble drugs is produced by combining the drug with a polymer carrier such as polyvinylpyrrolidone. The drug is combined with the carrier without the need for using organic solvents or melting temperatures (fusion) through the use of a transition compound such as polyethylene glycol which partially solubilizes the drug and/or plasticizes the polymer.

Solid pharmaceutical dispersions

An oral pharmaceutical composition is provided for treating hypercholestereolemia or hyperlipidemia containing an advantageous formulation for stabilizing the HMG-CoA coenzyme A inhibitor, CI-981 Hemi-Calcium, of formula (IA) ##STR1## with effective amounts of calcium carbonate. A method for preparing a CI-981 stabilizing composition is described.

Stable oral CI-981 formulation and process for preparing same

Stable oral CI-981 formulation and process of preparing same

The present invention pertains to a dual control sustained release drug delivery system which comprises a core and a porous coating layer over the core, wherein the coated core comprises (A) a core comprising in percentages by weight of the core composition (a) a medicament present in an amount from about 60% to about 90%; (b) an edible material having a melting point from about 25.degree. C. to about 100.degree. C. selected from the group consisting of (i) fatty acids having an iodine value from about 1 to about 10, (ii) natural waxes, (iii) synthetic waxes, and (iv) mixtures thereof, present in an amount from about 5% to about 40%; and (B) a porous coating layer over the core comprising in percentages by weight of the coating layer composition (a) a pH-independent water-insoluble polymer present in an amount from about 40% to about 80%; and (b) a water-soluble film forming polymer present in an amount from about 20% to about 60%.

Dual control sustained release drug delivery systems and methods for

The present invention pertains to semi-enteric drug delivery systems which comprise (a) an inert core, (b) a first coating layer over the core comprising a medicament, and (c) a second coating layer over the first coating layer comprising a mixture of methacrylic acid copolymer, type C, and povidone present in a ratio by weight of from about 2:1 to about 24:1, respectively.

Semi-enteric drug delivery systems and methods for preparing same

A new series of copolymers which are useful as coatings for solid dosage forms, for transdermal devices, for wound dressing materials, and for contact lenses. Also disclosed are methods for preparing monomers and polymers as well as pharmaceutical compositions containing such polymers.

Methylene pyrrolidone copolymers for contact lens and pharmaceutical

According to this invention, the combination of a solid particulate water insoluble drug with a solid fish gelatin coating is produced by coacervation of the fish gelatin. The fish gelatin being soluble at ambient temperatures provides a basis for relatively low temperature coacervation impossible with other gelatins. Coacervation is brought about by the addition of conventional coacervation agents and the coacervating suspension containing gelatin and the agents is rendered insoluble by the addition of a suitable fixative such as glutaraldehyde.

Water insoluble drugs coated by coacervated fish gelatin

A sustained release oral pharmaceutical composition consists essentially of a recompressed mixture of a water-sensitive pharmaceutical agent, a high molecular weight hydrophilic cellulose polymer, and a lubricant. The mixture is compressed into a unitary mass, comminuted, and recompressed into tablets without the use of solvents.

Sustained release pharmaceutical compositions

Improved thrombin formulations, stable at room temperature using stabilizing quantities of a polyol and a buffer at specific pHs are described wherein crude thrombin is first purified by two-stage ion exchange chromatography.

Purified thrombin preparations

Copolymers from n-alkyl-3-alkenylene-2-pyrrolidone

A coating composition and dosage form containing said coated composition and method for increasing the water permeability of a coated dosage form is described where the coating composition contains a water-dispersible polymer such as a copolymer of poly(meth)acrylic esters and water- insoluble inorganic substances such as kaolin wherein such coated particles are then overcoated with water-soluble hydrophilic polymers.

Coated dosage forms

According to this invention various hygroscopic malflavored drugs can be proceeded by a unique wet granulation process wherein a slurry of the drug in water is dried in combination with colloidal silicon dioxide and, in a particularly preferred embodiment microcrystalline cellulose with the colloidal silicon dioxide absorbing onto the drug particles.

Drug in combination with flavor masking agent and method for making same

The invention concerns a novel copolymer of N-morpholinoethyl methacrylate and 2-hydroxyethyl methacrylate which can be used in transdermal delivery systems or in oral controlled release products. The invention also concerns a process for preparing the copolymer and a method of using it to administer pharmaceutically active substances.

Transdermal drug delivery device comprising copolymers of

Ivermectin, an antiparasitic agent which is insoluble and unstable in water, is formulated in glycerol formal and propylene glycol. These liquid formulations are suitable for parenteral administration for the treatment of parasitic infections and demonstrate improved efficacy and a broadened spectrum over previous formulations.

Non-aqueous ivermectin formulation with improved antiparasitic activity

A new series of copolymers such as N-isopropyl-3-methylene-2-pyrrolidone and 2-hydroxyethylmethacrylate which are useful as coatings for solid dosage forms, for transdermal devices, for wound dressing materials, and for contact lenses. Also disclosed are methods for preparing monomers and polymers as well as pharmaceutical compositions containing such polymers.

Growing community of inventors

Somerville, NJ, United States of America

Russell U Nesbitt